Andrographolide in Sepsis: Mechanistic Basis, New Drug States, and Advanced Delivery Systems

Area of Science:

• Pharmacology
• Immunology
• Sepsis Research

Background:

• Sepsis is a major cause of preventable death, with limited adjunctive therapies available.
• Andrographolide, derived from Andrographis paniculata, exhibits anti-inflammatory, antioxidant, and endothelial-protective effects in preclinical models.

Purpose of the Study:

• To review the mechanistic basis and translational challenges of using andrographolide as an adjunctive sepsis therapy.
• To explore andrographolide's potential in modulating key inflammatory pathways and its pharmaceutical limitations.

Main Methods:

• Narrative review of preclinical and limited clinical data on andrographolide in sepsis.
• Examination of andrographolide's effects on Toll-like receptor 4 (TLR4) signaling, NF-κB/MAPK pathways, NLRP3 inflammasome, and mitochondrial stress.
• Analysis of andrographolide's pharmaceutical liabilities, including solubility and systemic exposure.

Main Results:

• Andrographolide modulates TLR4 signaling, restrains NLRP3 inflammasome, mitigates mitochondrial stress, and preserves endothelial barrier function.
• Partial maintenance of bacterial clearance was observed.
• Significant pharmaceutical challenges include extremely low aqueous solubility and limited systemic exposure.

Conclusions:

• Andrographolide demonstrates potential as an adjunctive sepsis therapy through multiple anti-inflammatory and protective mechanisms.
• Pharmaceutical liabilities necessitate the development of exposure-enabling strategies.
• Current evidence supports further translational exploration and hypothesis generation rather than immediate clinical use in sepsis.